Figure 3From: Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer Kaplan-Meier survival analyses of the patients who received adjuvant endocrine therapy with Tamoxifen. Disease-free survival (A) and overall survival (B) of the 176 patients who received adjuvant endocrine therapy with tamoxifen stratified according to expression of NAT1.Back to article page